BioCurex PRESS RELEASE
Source: BioCurex, Inc.
January 9, 2003
OTCBB Listed BioTech Companies BOCX & RJVN -
Creating a Non-Toxic Therapeutic Antibody Cancer
Treatment That May Arrest Development and Replication
of Cancerous Cells.
Rancho Santa Margarita, Calif., January 9, 2003 BioCurex,
Inc., (OTC BB:BOCX), Announces further developments
relating to its licensing agreement with BioKinetix,
a company being acquired by RJV Networks, Inc.,
(OTC BB : RJVN).
BioCurex and RJV networks (through Biokinetix) are
behind the development of a new therapeutic product,
which experts believe will arrest the development of
and replication of cancerous cells that cause the
growth of malignant tumors.
BOCX's proprietary technology has identified a New
Widespread Cancer marker Molecule named RECAF.
Cancer "markers" are molecules that appear on cancer
cells but not on normal cells and have been hailed as
The Holy Grail of cancer research since they can be
used to detect (diagnose) and then specifically target
cancer cells (therapy) - offering the potential to
provide treatment of cancer by delivering antibodies
to the targeted cancerous cells.
RJVN and BioKinetics have proprietary technology for
developing "superantibodies", an enhancement of antibody
technology that makes ordinary antibodies much more lethal.
The combination of anti-RECAF antibodies from BioCurex with
the superantibody technology from RJVN - BioKinetics is
expected to produce a powerful therapeutic agent to combat
most types of cancer.
If the antibodies prove to be cancer cell specific, it
is unlikely that there would be any adverse side effects.
This lack of toxicity should accelerate testing and
approval process.
Dr. Moro, President of Biocurex stated: "Our ultimate
goal is to fight cancer. We have the cancer marker that
identifies the cancer cells and RJV Networks-BioKinetix
has the superantibody technology to kill them. It is only
natural that we join forces in the battle against this
horrible disease. I see tremendous potential for success
in this joint effort.
Dr. John Todd, President of BioKinetix Corporation stated
that Bio Kinetix Corporation's mission is to acquire
intellectual property rights for existing products
and intellectual property. Then, through a series of
collaborative relationships, we will facilitate the
development of a new generation of monoclonal antibodies
(termed "Superantibodies), which will have a significantly
improved therapeutic potency as anticancer agents.
BioCurex, Inc.
Richard Moro, President
RJV Networks-BioKinetix
Grant Young
